Thanks Telmo,
this thing is way worse than the flu!
Sent from Yahoo Mail on Android
On Wed, Apr 8, 2020 at 12:56 AM, Telmo Menezes<te...@telmomenezes.net> wrote:
#yiv8943505836 p.yiv8943505836MsoNormal, #yiv8943505836
p.yiv8943505836MsoNoSpacing{margin:0;}Oh man... I am relived to read that you
are recovering. Hope that you are 100% healthy soon!
Best wishes,
Telmo
On Wed, Apr 8, 2020, at 01:39, 'Chris de Morsella' via Everything List wrote:
This virus is, for some, very serious. I live in one of the first affected
areas in King County, WA just miles from the epicenter.
My personal anecdotal experience:
My family contracted it, we are in isolation. For my wife and I, it was
serious, especially for me as it progressed into my lungs. Last weekend was
terrifying as my condition was rapidly deteriorating and I was struggling to
breath. My blood oxygen levels -- we have a sensor unit at home -- dropped
below 90 and my pulse rate, which for me, at rest, is normally around 60 went
up to above 80. Pleuritis set in and breathing felt like broken glass shards
were in the bottom of my lungs. At the covid emergency clinic I went to that
my provider has setup the doctors were worried and wanted me to go to the
hospital. It looked like pneumonia might have set in, but x-rays, they took,
thankfully ruled that out.
I am slowly recovering and my blood oxygen levels have climbed up out of the
real danger zone where sepsis can begin occurring. They fluctuate in a band
between 92-95, and my resting pulse rate has come back down towards 60 again.
Slowly but surely I am breathing easier and feel my health & life returning.
The pain from the pleuritis has gone way down as well.
I am lucky to have very good health insurance and to be working for a large
software company here that has been supportive as I've gone through this
ordeal.... and to be in a role that is important especially now. The division I
work for enables enterprises to operate in the cloud by providing a hybrid
identity service that can protect access to all their on-premises
applications/services by enabling authentication/authorization from remote
users through our cloud.
My wife did not get as sick as I did, but we are both suffering fatigue; our 16
year old daughter probably got this, but hardly felt anything.
For many people this may not be that serious, but others are dying.
Please stay safe and do your part to help hold the transmission rate down in
order to give our over-taxed medical systems the ability to handle the critical
load.
Last weekend was terrifying for me at a personal level, as I -- like everyone
else -- saw thise images of dead bodies piled up in make shift morgues....
thinkibg I could be one of them.
-Chris
A single vaccine factory can cost half a billion dollars and 44 vaccines are in
early stage development, and even after you find one that works and is safe
you're going to need billions of doses to vaccinate everybody. Because nobody
else is doing anything Bill Gates picked 7 out of those 44 that he thought were
most promising and decided to build factories right now for all 7 with full
knowledge that he will end up wasting billions of dollars. Gates said:
"Even though we’ll end up picking at most two of them, we’re going to fund
factories for all seven, just so that we don’t waste time in serially saying,
‘OK, which vaccine works?’ and then building the factory. We can start now by
building the facilities where these vaccines will be made. Because many of the
top candidates are made using unique equipment, we’ll have to build facilities
for each of them, knowing that some won’t get used. Private companies can’t
take that kind of risk, but the federal government can."
Gates can take the risk but so can the federal government, and they can do
things on an even larger scale than he can. And we're not going to get back to
normal until a vaccine is found and we're mass producing it. The following is
from an editorial in the March 27 2020 issue of the journal Science:
==
"There is an unprecedented race to develop a vaccine against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). With at least 44 vaccines in
early-stage development, what outcome can we expect? Will the first vaccine to
cross the finish line be the safest and most effective? Or will it be the most
well-funded vaccines that first become available, or perhaps those using
vaccine technologies with the fewest regulatory hurdles? The answer could be a
vaccine that ticks all these boxes. If we want to maximize the chances for
success, however, and have enough doses to end the coronavirus disease 2019
(COVID-19) pandemic, current piecemeal efforts won't be enough. If ever there
was a case for a coordinated global vaccine development effort using a “big
science” approach, it is now.
There is a strong track record for publicly funded, large-scale scientific
endeavors that bring together global expertise and resources toward a common
goal. The Manhattan Project brought about nuclear weapons quickly (although
with terrible implications for humanity) through an approach that led to
countless changes in how scientists from many countries work together. The
Human Genome Project and CERN (the European Organization for Nuclear Research)
engaged scientists from around the world to drive basic research from their
home labs through local and virtual teamwork. Taking this big, coordinated
approach to developing a SARS-CoV-2 vaccine will not only potentially save
hundreds of thousands of lives, but will also help the world be better prepared
for the next pandemic.
An initiative of this scale won't be easy. Extraordinary sharing of information
and resources will be critical, including data on the virus, the various
vaccine candidates, vaccine adjuvants, cell lines, and manufacturing advances.
Allowing different efforts to follow their own leads during the early stages
will take advantage of healthy competition that is vital to the scientific
endeavor. We must then decide which vaccine candidates warrant further
exploration purely on the basis of scientific merit. This will require drawing
on work already supported by many government agencies, independent
organizations like the Coalition for Epidemic Preparedness Innovations, and
pharmaceutical and biotech companies to ensure that no potentially important
candidate vaccines are missed. Only then can we start to narrow in on those
candidates to be advanced through all clinical trial phases. This shortlist
also needs to be based on which candidates can be developed, approved, and
manufactured most efficiently.
Trials need to be carried out in parallel, not sequentially, using adaptive
trial designs, optimized for speed and tested in different populations—rich and
developing countries, from children to the elderly—so that we can ultimately
protect everyone. Because the virus is spreading quickly, testing will be
needed in communities where we can get answers fast—that means running trials
anywhere in the world, not just in preset testing locations. Working with
regulators early in the process will increase the likelihood of rapid
approvals, and then once approved, a coordinated effort will ensure that
sufficient quantities are available to all who need the vaccine, not just to
the highest bidder.
All of this will require substantial funding, which is the big ask of big
science. Late-stage clinical trials are not cheap, nor is vaccine
manufacturing. Although new modular manufacturing methods may speed up the
process and cut costs, a single vaccine facility can cost half a billion
dollars. Distribution comes at a cost, too. So, to guarantee sufficient
production of SARS-CoV-2 vaccines, incentives are needed to engage
manufacturers for large-scale capacity. As for dissemination, those
organizations with experience in global vaccine distribution, like Gavi, will
be at the ready.
Ideally, this effort would be led by a team with a scientific advisory
mechanism of the highest quality that could operate under the auspices of the
World Health Organization (WHO), for example. But none of this will be possible
without political will and a global commitment from leaders of the G7 and G20
countries and multilateral organizations, like the WHO and the World Bank. A
pandemic of this magnitude, affecting so many lives, livelihoods, and
economies, demands this.
In many ways, COVID-19 is more like the Manhattan Project than other big
science efforts, not just because it involves the application of science and
not just in terms of scale, but because it is a global security issue. In the
race to develop a SARS-CoV-2 vaccine, everyone must win."
John K Clark
--
You received this message because you are subscribed to the Google Groups
"Everything List" group.
To unsubscribe from this group and stop receiving emails from it, send an
email to everything-list+unsubscr...@googlegroups.com.
To view this discussion on the web visit
https://groups.google.com/d/msgid/everything-list/CAJPayv0cGJQUF2QHJZGGMDfs%3DOWbeCFbPk1Xqn-bBsw0JxxVRg%40mail.gmail.com.
--
You received this message because you are subscribed to the Google Groups
"Everything List" group.
To unsubscribe from this group and stop receiving emails from it, send an
email to everything-list+unsubscr...@googlegroups.com.
To view this discussion on the web visit
https://groups.google.com/d/msgid/everything-list/342091937.2238861.1586309943934%40mail.yahoo.com.
--
You received this message because you are subscribed to the Google Groups
"Everything List" group.
To unsubscribe from this group and stop receiving emails from it, send an email
to everything-list+unsubscr...@googlegroups.com.
To view this discussion on the web visit
https://groups.google.com/d/msgid/everything-list/3a3de3cb-cc59-47f5-9ee6-198a2e10e128%40www.fastmail.com.
--
You received this message because you are subscribed to the Google Groups
"Everything List" group.
To unsubscribe from this group and stop receiving emails from it, send an email
to everything-list+unsubscr...@googlegroups.com.
To view this discussion on the web visit
https://groups.google.com/d/msgid/everything-list/968790099.3502419.1586472121335%40mail.yahoo.com.
